<p>随着美国市场经历波动期，主要指数因对人工智能泡沫和即将发布的经济报告的担忧而收盘下跌，投资者密切关注科技行业的动态。在这样的环境下，识别高增长科技股需要寻找基本面强劲且能抵御市场压力的公司。</p>
<h3>美国十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA Biologics</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.15%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国高增长科技和人工智能股票筛选器的 76 只股票完整列表。</p>
<p>在这里，我们突出显示了筛选器中我们首选股票的一个子集。</p>
<h2>Precigen (PGEN)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Precigen, Inc. 是一家发现和临床阶段的生物制药公司，专注于开发用于免疫肿瘤学、自身免疫疾病和传染病的基因和细胞疗法，市值为 13.5 亿美元。</p>
<p><strong>运营：</strong> Precigen 专注于利用精准技术开发基因和细胞疗法，以应对免疫肿瘤学、自身免疫疾病和传染病。</p>
<p>尽管目前尚未盈利，Precigen 展现出良好的增长潜力，预计年收入增长 55.8%，远超美国市场平均水平 10.5%。这一增长得益于生物技术的重大进展，FDA 已批准 PAPZIMEOS™用于治疗复发性呼吸道乳头状瘤病，这是该领域的首个产品。公司的创新承诺通过相对于其收入的可观研发投资进一步得以体现，使其在竞争激烈的行业环境中为未来的突破和财务成功奠定了良好基础。</p>
<ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Precigen 的动态。</li>
<li>通过我们的历史报告获取对 Precigen 过去趋势和表现的洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 PGEN 收入和支出明细</p>
<h2>Roivant Sciences (ROIV)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Roivant Sciences Ltd. 是一家临床阶段的生物制药公司，致力于药物和技术的发现、开发和商业化，市值为 152.3 亿美元。</p>
<p><strong>运营：</strong> Roivant Sciences 专注于药物和技术的发现、开发和商业化，主要通过这些活动产生收入。该公司的市值为 152.3 亿美元。</p>
<p>在充满挑战的环境中，Roivant Sciences 展现出强大的潜力，预计年收入增长 58.5%，显著高于美国市场平均水平 10.6%。尽管目前尚未盈利，预计盈利将年增长 46.44%。最近的进展包括 Brepocitinib 在皮肌炎中的积极试验结果，以及 Mosliciguat 在肺动脉高压中的二期临床试验，奠定了 2026 年及以后关键 FDA 申请和商业发布的基础。这些进展突显了 Roivant 通过创新疗法解决关键医疗需求的承诺，使其在生物技术行业的未来格局中处于有利位置。</p>
<ul>
<li>点击这里通过我们的详细分析健康报告发现 Roivant Sciences 的细微差别。</li>
<li>通过访问我们的历史表现报告评估 Roivant Sciences 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d84a70b-7896-4d8a-a33c-af4937623fd1/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d84a70b-7896-4d8a-a33c-af4937623fd1/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 ROIV 盈利和收入增长</p>
<h2>Semrush Holdings (SEMR)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Semrush Holdings, Inc. 提供在线可见性管理 SaaS 平台，在美国、英国及国际市场运营，市值约为 17.7 亿美元。</p>
<p><strong>运营：</strong> 该公司主要通过其软件和编程部门产生收入，该部门带来了 4.2863 亿美元。其运营专注于在各个地区提供全面的在线可见性管理 SaaS 平台。</p>
<p>在行业的一项重大举措中，Semrush Holdings 最近被 Adobe 以 20 亿美元收购，继续在人工智能和搜索引擎优化的交汇处进行创新。尽管今年净亏损，Semrush 报告收入强劲增长至 3.2599 亿美元，较去年 2.7417 亿美元有所上升，突显其在快速发展的科技环境中的韧性和适应能力。'Semrush One'的推出将传统 SEO 与人工智能驱动的搜索能力相结合，承诺在包括 ChatGPT 等主要大型语言模型在内的各种平台上增强在线可见性。这一战略扩展不仅多样化了 Semrush 的产品，还使其在数字营销领域中占据了强有力的位置，因为企业越来越依赖复杂的工具来应对互联网可见性和品牌参与的复杂性。</p>
<ul>
<li>解锁我们对 Semrush Holdings 股票分析的全面见解，查看此健康报告。</li>
<li>了解 Semrush Holdings 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ea1498cd-82af-446b-851a-9bbea9898ae1/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ea1498cd-82af-446b-851a-9bbea9898ae1/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 SEMR 收入和支出明细</p>
<h2>将想法转化为行动</h2>
<ul>
<li>点击这里访问我们完整的 76 只美国高增长科技和人工智能股票索引。</li>
<li>对这些企业有投资吗？将您的持股整合到 Simply Wall St 的投资组合中，以获取通知和详细的股票报告。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会的世界，并获取各市场无与伦比的股票分析。</li>
</ul>
<h2>寻找新的视角？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>移动基础设施用于国防和灾难</p>
<p>下一波机器人技术不是类人机器人。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

PLTR

<p>这篇文章强调了美国市场波动中高增长科技股，重点关注基本面强劲的公司。它列出了像 ADMA Biologics、Marker Therapeutics 和 Palantir Technologies 等顶尖公司，并指出了它们的收入和盈利增长。文章还介绍了 Precigen、Roivant Sciences 和 Semrush Holdings，详细说明了它们的运营和增长潜力。文章强调了创新和战略扩展在科技行业中的重要性，并通过 Simply Wall St 的分析工具提供了投资机会的见解</p>

<p>As the United States market navigates a period of volatility, with major indexes closing lower amid concerns over an AI bubble and looming economic reports, investors are keenly observing the tech sector's dynamics. In such a climate, identifying high-growth tech stocks involves looking for companies with strong fundamentals and resilience to market pressures.</p>
<div class="lb-trans"><p>随着美国市场经历波动期，主要指数因对人工智能泡沫和即将发布的经济报告的担忧而收盘下跌，投资者密切关注科技行业的动态。在这样的环境下，识别高增长科技股需要寻找基本面强劲且能抵御市场压力的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美国十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA Biologics</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.15%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA Biologics</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.15%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 76 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国高增长科技和人工智能股票筛选器的 76 只股票完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在这里，我们突出显示了筛选器中我们首选股票的一个子集。</p>
</div><h2>Precigen (PGEN)</h2>
<div class="lb-trans"><h2>Precigen (PGEN)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $1.35 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Precigen, Inc. 是一家发现和临床阶段的生物制药公司，专注于开发用于免疫肿瘤学、自身免疫疾病和传染病的基因和细胞疗法，市值为 13.5 亿美元。</p>
</div><p><strong>Operations:</strong> Precigen focuses on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases.</p>
<div class="lb-trans"><p><strong>运营：</strong> Precigen 专注于利用精准技术开发基因和细胞疗法，以应对免疫肿瘤学、自身免疫疾病和传染病。</p>
</div><p>Despite its current unprofitability, Precigen demonstrates promising growth potential with an expected revenue increase of 55.8% per year, outpacing the US market average of 10.5%. This growth is bolstered by significant advancements in biotechnology, as evidenced by the FDA approval of PAPZIMEOS™ for treating recurrent respiratory papillomatosis—a first in its class. The company's commitment to innovation is further highlighted by a substantial R&amp;D investment relative to its revenue, positioning it well for future breakthroughs and financial success in a competitive industry landscape.</p>
<div class="lb-trans"><p>尽管目前尚未盈利，Precigen 展现出良好的增长潜力，预计年收入增长 55.8%，远超美国市场平均水平 10.5%。这一增长得益于生物技术的重大进展，FDA 已批准 PAPZIMEOS™用于治疗复发性呼吸道乳头状瘤病，这是该领域的首个产品。公司的创新承诺通过相对于其收入的可观研发投资进一步得以体现，使其在竞争激烈的行业环境中为未来的突破和财务成功奠定了良好基础。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Precigen.</li>
<li>Gain insights into Precigen's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整健康分析报告，以了解 Precigen 的动态。</li>
<li>通过我们的历史报告获取对 Precigen 过去趋势和表现的洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/revenue-and-expenses-breakdown"/></p>
<p>PGEN Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 PGEN 收入和支出明细</p>
</div><h2>Roivant Sciences (ROIV)</h2>
<div class="lb-trans"><h2>Roivant Sciences (ROIV)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of medicines and technologies, with a market cap of $15.23 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Roivant Sciences Ltd. 是一家临床阶段的生物制药公司，致力于药物和技术的发现、开发和商业化，市值为 152.3 亿美元。</p>
</div><p><strong>Operations:</strong> Roivant Sciences focuses on the discovery, development, and commercialization of medicines and technologies, generating revenue primarily from these activities. The company has a market cap of $15.23 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> Roivant Sciences 专注于药物和技术的发现、开发和商业化，主要通过这些活动产生收入。该公司的市值为 152.3 亿美元。</p>
</div><p>Roivant Sciences, amidst a challenging landscape, showcases robust potential with an anticipated 58.5% annual revenue growth, significantly outpacing the U.S. market's average of 10.6%. Despite current unprofitability, earnings are expected to surge by 46.44% annually. Recent strides include positive trial outcomes for Brepocitinib in dermatomyositis and ongoing Phase 2 trials for Mosliciguat in pulmonary hypertension, setting the stage for pivotal FDA filings and commercial launches slated for early 2026 and beyond. These developments underscore Roivant's commitment to addressing critical medical needs through innovative therapies, positioning it favorably within the biotech sector's future landscape.</p>
<div class="lb-trans"><p>在充满挑战的环境中，Roivant Sciences 展现出强大的潜力，预计年收入增长 58.5%，显著高于美国市场平均水平 10.6%。尽管目前尚未盈利，预计盈利将年增长 46.44%。最近的进展包括 Brepocitinib 在皮肌炎中的积极试验结果，以及 Mosliciguat 在肺动脉高压中的二期临床试验，奠定了 2026 年及以后关键 FDA 申请和商业发布的基础。这些进展突显了 Roivant 通过创新疗法解决关键医疗需求的承诺，使其在生物技术行业的未来格局中处于有利位置。</p>
</div><ul>
<li>Click here to discover the nuances of Roivant Sciences with our detailed analytical health report.</li>
<li>Evaluate Roivant Sciences' historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里通过我们的详细分析健康报告发现 Roivant Sciences 的细微差别。</li>
<li>通过访问我们的历史表现报告评估 Roivant Sciences 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d84a70b-7896-4d8a-a33c-af4937623fd1/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/1d84a70b-7896-4d8a-a33c-af4937623fd1/chart/earnings-and-revenue-growth"/></p>
<p>ROIV Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ROIV 盈利和收入增长</p>
</div><h2>Semrush Holdings (SEMR)</h2>
<div class="lb-trans"><h2>Semrush Holdings (SEMR)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Semrush Holdings, Inc. offers an online visibility management SaaS platform operating in the United States, the United Kingdom, and internationally with a market cap of approximately $1.77 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Semrush Holdings, Inc. 提供在线可见性管理 SaaS 平台，在美国、英国及国际市场运营，市值约为 17.7 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its software and programming segment, which brought in $428.63 million. Its operations focus on providing a comprehensive SaaS platform for online visibility management across various regions.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其软件和编程部门产生收入，该部门带来了 4.2863 亿美元。其运营专注于在各个地区提供全面的在线可见性管理 SaaS 平台。</p>
</div><p>In a significant industry move, Semrush Holdings, recently acquired by Adobe for $2 billion, continues to innovate at the intersection of AI and search engine optimization. Despite a net loss this year, Semrush reported a robust revenue increase to $325.99 million, up from $274.17 million last year, underlining its resilience and adaptability in a rapidly evolving tech landscape. The launch of 'Semrush One' integrates traditional SEO with AI-driven search capabilities, promising enhanced online visibility across various platforms including major LLMs like ChatGPT. This strategic expansion not only diversifies Semrush's offerings but also positions it strongly within the digital marketing sphere as businesses increasingly rely on sophisticated tools to navigate the complexities of internet visibility and brand engagement.</p>
<div class="lb-trans"><p>在行业的一项重大举措中，Semrush Holdings 最近被 Adobe 以 20 亿美元收购，继续在人工智能和搜索引擎优化的交汇处进行创新。尽管今年净亏损，Semrush 报告收入强劲增长至 3.2599 亿美元，较去年 2.7417 亿美元有所上升，突显其在快速发展的科技环境中的韧性和适应能力。'Semrush One'的推出将传统 SEO 与人工智能驱动的搜索能力相结合，承诺在包括 ChatGPT 等主要大型语言模型在内的各种平台上增强在线可见性。这一战略扩展不仅多样化了 Semrush 的产品，还使其在数字营销领域中占据了强有力的位置，因为企业越来越依赖复杂的工具来应对互联网可见性和品牌参与的复杂性。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Semrush Holdings stock in this health report.</li>
<li>Learn about Semrush Holdings' historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对 Semrush Holdings 股票分析的全面见解，查看此健康报告。</li>
<li>了解 Semrush Holdings 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ea1498cd-82af-446b-851a-9bbea9898ae1/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/ea1498cd-82af-446b-851a-9bbea9898ae1/chart/revenue-and-expenses-breakdown"/></p>
<p>SEMR Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 SEMR 收入和支出明细</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>将想法转化为行动</h2>
</div><ul>
<li>Click here to access our complete index of 76 US High Growth Tech and AI Stocks.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们完整的 76 只美国高增长科技和人工智能股票索引。</li>
<li>对这些企业有投资吗？将您的持股整合到 Simply Wall St 的投资组合中，以获取通知和详细的股票报告。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会的世界，并获取各市场无与伦比的股票分析。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>寻找新的视角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人机器人。它是完全自主的塔，在 30 分钟内提供 5G、ISR 和雷达服务，覆盖任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

US High Growth Tech Stocks To Watch December 2025

- 美国市场面临波动，主要指数疲软，投资者关注科技板块动态。  
- 前十高增长科技公司包括 ADMA Biologics 和 Marker Therapeutics，分别实现 20.12% 和 75.24% 的收入增长。  
- Precigen 和 Roivant Sciences 等公司具备强劲增长潜力，预计年收入增长超过 58%。

2025 年 12 月值得关注的美国高增长科技股票